Iwamoto, Takayuki
Niikura, Naoki
Watanabe, Kenichi
Takeshita, Takashi
Kikawa, Yuichiro
Kobayashi, Kokoro
Iwakuma, Nobutaka
Okamura, Takuho
Kobayashi, Takayuki
Katagiri, Yuriko
Kitada, Masahiro
Tomioka, Nobumoto
Miyoshi, Yasuo
Shigematsu, Hideo
Miyashita, Minoru
Ishiguro, Hiroshi
Masuda, Norikazu
Saji, Shigehira
Funding for this research was provided by:
Pfizer Inc.
AstraZeneca United States
Article History
Received: 28 February 2024
Accepted: 17 June 2024
First Online: 26 June 2024
Declarations
:
: Grants or contracts from any entityNN: Chugai, Pfizer, Eisai, Mochida, Daiichi Sankyo, Novartis; YMDaiichi-Sankyo, Eisai, Chugai, MSD, Kyowa-Kirin, Eli Lilly, Taiho; HI: Eisai Co., Ltd., Daiichi sankyo co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, AstraZeneca plc, MSD K.K., AstraZeneca plc, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd.., Chugai Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma K.K., Sawai Pharmaceutical Co., Ltd., Covance Japan Co., Ltd., Maruho Co.,Ltd., LabCorp Japan, G.K., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly Japan KK; NM: Chugai, Eli Lilly, Astra Zeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Gilead Sciences, Ono-Pharma; SS: Taiho, Eisai, Chugai, Takeda, MSD, Astra Zeneca, Daiichi Sankyo. Payment or honoraria NN: Chugai, Eli Lilly, MSD, Daiichi-Sankyo, AstraZeneca, Pfizer; KW: Chugai, Eli Lilly, Nippon-Kayaku, Kyowa-Kirin, Novartis, Taiho, Eisai, Pfizer, Shionogi, Daiichi-Sankyo, AstraZeneca; YK: Eisai, Daiichi Sankyo, Lilliy, Chugai, Pfizer, AstraZeneca, Taiho; KK: Pfizer, Eli lily, Taiho, AstraZeneca, Eisai, Chugai, Novartis: YM: Daiichi-Sankyo, Chugai, Eisai, Eli Lilly, AstraZeneca, Pfizer, Taiho, Kyowa-Kirin; MM: Chugai, Eli Lilly, MSD, Daiichi Sankyo, AstraZeneca, Pfizer, Taiho, Eisai; HI: Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Kyowa Kirin Co., Ltd., Daiichi sankyo co., Ltd., Taiho Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, AstrazenecaKK, MSD K.K; NM: Chugai, Pfizer, Astra Zeneca, Eli Lilly, Daiichi Sankyo; SS: Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, Nipponkayaku Leadership or fiduciary role NM: JBCRG, Japanese Breast Cancer Society (JBCS), Japan Society of Clinical Oncology (JSCO); SS: JBCRG, JBCS, JSMO, BIG The other authors have no competing interests.Grants or contracts from any entityNN: Chugai, Pfizer, Eisai, Mochida, Daiichi Sankyo, Novartis; YM: Daiichi-Sankyo, Eisai, Chugai, MSD, Kyowa-Kirin, Eli Lilly, Taiho; HI: Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, AstraZeneca Plc, MSD K.K., AstraZeneca Plc, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd.., Chugai Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma K.K., Sawai Pharmaceutical Co., Ltd., Covance Japan Co., Ltd., Maruho Co., Ltd., LabCorp Japan, G.K., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly Japan KK; NM: Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Gilead Sciences, Ono-Pharma; SS: Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, Daiichi Sankyo.Payment or honorariaNN: Chugai, Eli Lilly, MSD, Daiichi-Sankyo, AstraZeneca, Pfizer; KW: Chugai, Eli Lilly, Nippon-Kayaku, Kyowa-Kirin, Novartis, Taiho, Eisai, Pfizer, Shionogi, Daiichi-Sankyo, AstraZeneca; YK: Eisai, Daiichi Sankyo, Lilliy, Chugai, Pfizer, AstraZeneca, Taiho; KK: Pfizer, Eli lily, Taiho, AstraZeneca, Eisai, Chugai, Novartis: YM: Daiichi-Sankyo, Chugai, Eisai, Eli Lilly, AstraZeneca, Pfizer, Taiho, Kyowa-Kirin; MM: Chugai, Eli Lilly, MSD, Daiichi Sankyo, AstraZeneca, Pfizer, Taiho, Eisai; HI: Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer, Inc., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K., MSD K.K; NM: Chugai, Pfizer, AstraZeneca, Eli Lilly, Daiichi Sankyo; SS: Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho, Ono, Nippon Kayaku.Leadership or fiduciary roleNM: JBCRG, Japanese Breast Cancer Society (JBCS), Japan Society of Clinical Oncology (JSCO); SS: JBCRG, JBCS, JSMO, BIG.The other authors have no competing interests.
: This study received an approval from the Ethics Committee of Fukushima Medical University School of Medicine, Okayama University Hospital and the respective institution.
: Informed consent was obtained from all individual participants included in the study.